December 23, 2009 (FinancialWire) — The Advanced Wound Management division of Smith & Nephew plc (NYSE: SNN) said that its affiliates have completed the acquisition of substantially all of the assets of Nucryst Pharmaceuticals Corp. (NASDAQ: NCST).

The acquisition includes the manufacturing assets from Nucryst’s Fort Saskatchewan, Canada operations and the intellectual property estate.

Since 2001, Smith & Nephew has held exclusive license for the sale of the ACTICOAT™ dressing portfolio, manufactured at the Ft. Saskatchewan site. This acquisition gives its Advanced Wound Management unit full control over all the intellectual property rights, manufacturing and assets relating to the nanocrystalline silver technology that is incorporated in Acticoat, which is the second largest brand in the Smith & Nephew Advanced Wound Management product portfolio.

Smith & Nephew is a medical technology business. The company operates in 32 countries around the world.  

Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). Recently issued reports and filings include F & C Capital & Income Investment Trust PLC (LSE: FCI), Sarantel Group PLC (LSE: SLG), Pharmacyclics, Inc. (NASDAQ: PCYC), Niusule Biotech Corp. (OTCBB: NIUS), JPMorgan European Investment Trust PLC (LSE: JFF), Ecofin Water & Power Opportunities PLC (LSE: ECWO), Invesco Property Income Trust Ltd. (LSE: IPI), Hansa Trust PLC (LSE: HAN) (OTC: FSBTF), Perpetual Income & Growth Investment Trust PLC (LSE: PLI), New India Investment Trust PLC (LSE: NII), JPMorgan Fleming Smaller Japanese Companies Investment Trust PLC (LSE: JPS), Edinburgh Investment Trust PLC (LSE: EDIN) (OTC: EHITF), Armour Group PLC (LSE: AMR), Bravo Venture Group Inc. (TSX Venture: BVG), Bellway PLC (London Stock Exchange: BWY) (OTC: BLWYF), Chase Corp. (AMEX: CCF), Continental Materials Corp. (AMEX: CUO), Amcon Distributing Company (AMEX: DIT), Eaton Vance Enhanced Equity Income Fund (NYSE: EOI), Majedie Investments PLC (London Stock Exchange: MAJE) (OTC: MJENF), Morgan Stanley Income Securities, Inc. (NYSE: ICB), Grainger PLC (London Stock Exchange: GRI) (OTC: GRTGF), Eaton Vance Insured Municipal Bond Fund (AMEX: EIM), PIMCO High Income Fund (NYSE: PHK) and Shaw Communications, Inc. (NYSE: SJR).

FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors by the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/). Recently webcast company presentations, financial results & earnings calls now available include InSite Vision, Inc. (OTCBB: INSV), LocatePLUS Holdings, Inc. (OTC: LPHC), Rentech, Inc. (AMEX: RTK), CytRx Corp. (NASDAQ: CYTR), Santarus, Inc. (NASDAQ: SNTS) ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX), Aastrom Biosciences, Inc. (NASDAQ: ASTM), Methode Electronics, Inc. (NYSE: MEI), White Electronic Designs Corp. (NASDAQ: WEDC), Cantel Medical Corp. (EXCH: CMN), Frequency Electronics Inc. (EXCH: FEIM), Pep Boys-Manny, Moe & Jack (NYSE: PBY) and Xeta Technologies, Inc. (NASDAQ: XETA). Recordings are accessible via the search function at http://infoescrow.net/f/?u=http://www.investorcalendar.com by entering any company’s ticker symbol into the search field.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.